Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07128615 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)
A Phase 1 study of Influenza a, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 1
- Development phase
- 405
- Enrollment target
- 14
- Study locations
NCT07128615: Active Phase 1 study of Influenza a, sponsored by AstraZeneca.
NCT07128615 is a Phase 1 study of Influenza a that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 405 participants, below the 2,714-participant average among 10 other Influenza a trials with a reported enrollment target (85% lower). The trial reports 14 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07128615, a Phase 1 study of Influenza a, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 405 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity of two investigational vaccines, AZD4117 and AZD5315 to protect against certain strains of avian Influenza A (H5N1 and H7N9 subtypes).
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL AZD4117
- BIOLOGICAL AZD5315
Study Locations (14)
California
- Research Site - Long Beach
- Research Site - Rolling Hills Estates
Florida
- Research Site - Hialeah
Georgia
- Research Site - Stockbridge
Illinois
- Research Site - Chicago
Kansas
- Research Site - Lenexa
Missouri
- Research Site - Kansas City
Nebraska
- Research Site - Omaha
Nevada
- Research Site - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 405 participants |
| Start Date | 2025-09-04 |
| Est. Completion | 2026-12-29 |
| Phase | Phase 1 |
What the registry record for NCT07128615 still lists
NCT07128615 is an interventional study that assigns participants to a tested intervention. The registered 405 participants enrollment target is mid-sized for trials with a published cap, below the 2,714-participant average among 10 other Influenza a trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Influenza a appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07128615 lists 14 locations in 13 states (California, Florida, Georgia).
Frequently Asked Questions
What is clinical trial NCT07128615 about?
NCT07128615 is a clinical study titled "A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)". The purpose of this study is to evaluate the safety and immunogenicity of two investigational vaccines, AZD4117 and AZD5315 to protect against certain strains of avian Influenza A (H5N1 and H7N9 subtypes).
What is the current status of trial NCT07128615?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 405 participants. The study started on 2025-09-04. Estimated completion is 2026-12-29.
What conditions does trial NCT07128615 study?
This clinical trial studies the following conditions: Influenza a.
What interventions are being tested in trial NCT07128615?
The interventions under investigation include: Placebo (OTHER), AZD4117 (BIOLOGICAL), AZD5315 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07128615?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07128615 being conducted?
This trial has 14 study locations across California, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza a
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07128615's enrollment target sits among peer trials
405 6th of 10 higher than 5 of 10 other Influenza a trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza a trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines
COMPLETED · Phase 1
-
Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7
COMPLETED · Phase 1
-
A Multi-Site Clinical Evaluation of the LIAISON NES FLU A/B, RSV & COVID-19 Assay in Symptomatic Patients
RECRUITING · NA
-
Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Between Passively-collected Data From Wearable Activity Devices and Respiratory Viral Infections
COMPLETED
-
Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza
COMPLETED · Phase 3
-
Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05576350 · 405 participants · NA
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
- NCT07066657 · 405 participants · Phase 1
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- NCT06223360 · 406 participants · Phase 2
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
- NCT06411769 · 406 participants · NA
Evidence-based Intervention to Improve Walking Engagement in El Paso, Texas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI